Aster DM Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, recommended Final Dividend of Re. 1/- per equity share.
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aster DM Healthcare's board approved audited FY25 results and recommended a final dividend of Re. 1 per share (face value Rs. 10), subject to shareholder approval. On a standalone basis, revenue from operations grew about 14% to Rs. 2,320.48 crores in FY25 from Rs. 2,036.50 crores a year ago, while Q4 FY25 revenue rose modestly to Rs. 573.86 crores. Standalone profit after tax jumped to Rs. 6,208.97 crores in FY25 (vs Rs. 156.96 crores) and Rs. 61.07 crores in Q4 FY25 (vs a Rs. 8.11 crores loss), largely driven by a one-time Rs. 5,569.96 crores dividend received after the sale of the GCC business completed in April 2024. The company booked Rs. 323.15 crores of net exceptional items, including a Rs. 372.70 crores gain on preference share redemption and Rs. 49.55 crores of merger-related expenses. The board also confirmed completion of the Quality Care India (QCIL) merger on April 30, 2025, acquiring it for Rs. 849.13 crores via a preferential share allotment to BCP and TPG, and approved three new wholly owned subsidiaries. Auditor Deloitte Haskins & Sells issued an unmodified (clean) opinion on the results.
Shareholders will receive a total cash dividend of Rs. 5 per share in FY25 (Rs. 4 interim + Rs. 1 final), following the much larger Rs. 118 special dividend paid out of GCC sale proceeds. The headline profits are not recurring and are inflated by the one-time subsidiary dividend, so the stock reaction will likely hinge on the India operations' underlying growth, the completed QCIL merger scaling, and execution of the new subsidiaries rather than the headline PAT.